Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group obtained marketing approval for the Peceleganan Spray, according to a Tuesday Hong Kong bourse filing.
The drug was developed under an exclusive partnership by Chia Tai Tianqing Pharmaceutical.
The approval is for the treatment of wound infections secondary to first-degree or superficial second-degree burns and scalds caused by Staphylococcus epidermidis, Staphylococcus haemolyticus and Acinetobacter baumannii.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments